Skip to main content
TELO logo

Telomir Pharmaceuticals, Inc. (TELO) Stock Price & Analysis

Telomir Pharmaceuticals, Inc. (TELO) — MoonshotScore 48/100 (Fair band), calculated Nov 22, 2026. Price $0.364 (-17.24%), as of the Nov 20, 2026 trading session; market cap $26.8M.

Educational signal · not a buy or sell recommendation · How to read this

$0.364 −$0.0758 (-17.24%) Market Cap $26.8M

Telomir Pharmaceuticals, Inc. · TELO · NASDAQ

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on developing therapeutic treatments for human stem cells.

Price as of Nov 20, 2026

Key Statistics

48 of 100

MoonshotScore v2 · Telomir Pharmaceuticals (TELO)

Fair
Business Quality Thin (25)
Financial Safety Fortress (94)
Valuation Rich (36)
Growth Durability Shrinking (10)
Momentum Slipping (23)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet, but weak quality, stalling growth and an expensive valuation, and the price trend has turned against it. Business Quality: Thin; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Shrinking; Momentum: Slipping.

  • EPS beat 4 of the last 8 reports
  • Altman Z 51.81 · Piotroski F 2

Holding back: weak fundamentals, soft growth, weak price trend

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TELO (58 recorded, newest six shown)
RecordedScoreBand
52Fair
51Fair
51Fair
48Fair
48Fair
48Fair

The score was 48 in the stored Nov 21, 2026 snapshot and remains 48 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Valuation -2 and Growth Durability +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.364
Change on the day-17.24%
Market capitalisation$26.8M—
Shares traded on the day255.9K

Price & events

Other perspectives

Council score for Telomir Pharmaceuticals (TELO): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Strong
Valuation Weak
Growth Durability Negative
Momentum Weak

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Telomir Pharmaceuticals (TELO), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Telomir Pharmaceuticals, Inc. (TELO) is listed on NASDAQ. The market values it at $26.8M.

2 · Latest results

What do the latest results show for Telomir Pharmaceuticals (TELO)?

Short answer · as of

Against analyst estimates the company has EPS beat 4 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Telomir Pharmaceuticals (TELO)?

Short answer · as of

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z 51.81 · Piotroski F 2. Trailing ratios: current ratio 19.60 · earnings yield -16.2% · free-cash-flow yield -12.7%.

Data-derived red flags

  • Listing risk — at $0.364 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Telomir Pharmaceuticals (TELO)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $1.50M · EPS -0.11 · 1 analysts. The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for TELO.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Telomir Pharmaceuticals compare with its peers?

Short answer

Telomir Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.09 Nov 20, 2026$462M92 5-pillar Nov 22, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 22, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 22, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M87 5-pillar Nov 22, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.47 Nov 20, 2026$83.3M82 5-pillar Nov 22, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 22, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.57 Nov 20, 2026$155M72 5-pillar Nov 22, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M70 5-pillar Nov 22, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 22, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 22, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M64 5-pillar Nov 22, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.43 Nov 20, 2026$1.02B64 5-pillar Nov 22, 2026
Telomir Pharmaceuticals (TELO) — this page$0.364$26.8M48

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$4.00 – $4.00
Last captured analyst target (expired, captured Nov 18, 2026)
$4.00
Last captured median analyst target (expired, captured Nov 18, 2026)
$4.00
Revenue estimate
$1.50M
EPS estimate
$-0.11

Historical target record · Captured · Capture expired; not a current watchpoint.

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
4
Purchases
0
Sales
0
Other transactions
12

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TELO in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported TELO in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Telomir Pharmaceuticals (TELO)?

Read these with our analysis →

Common Questions About TELO

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for TELO?

TELO carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is TELO a good stock to buy?

Stock Expert AI does not rate TELO buy, sell or hold. Telomir Pharmaceuticals, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the TELO stock price today?

The last price recorded for Telomir Pharmaceuticals, Inc. (TELO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the TELO price target?

The last analyst consensus price target we captured for Telomir Pharmaceuticals, Inc. (TELO), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

What are the key factors to evaluate for TELO?

Telomir Pharmaceuticals, Inc. (TELO) holds a MoonshotScore in the low range. Telomir Pharmaceuticals is a pre-clinical stage company, indicating a high-risk, high-reward profile. Not financial advice.

How frequently does TELO data refresh on this page?

TELO's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven TELO's recent stock price performance?

Telomir Pharmaceuticals, Inc. (TELO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapeutic approach targeting stem cells. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider TELO overvalued or undervalued right now?

Telomir Pharmaceuticals, Inc. (TELO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of TELO?

Fractional-share availability for Telomir Pharmaceuticals, Inc. (TELO) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.